Table 3.
Major trials in HCC involving anti-PD-L1 agents-based immunotherapies.
| Name | Phase | Line of Treatment | Strategy | Primary Endpoint |
|---|---|---|---|---|
| NCT03638141 | 2 | II | Durvalumab (anti PD-L1)+ Tremelimumab (anti CTLA-4) | ORR (Objective Response Rate) |
| NCT03298451 | 3 | I | Durvalumab +/− Tremelimumab | OS (Overall Survival) |
| NCT03847428 | 3 | I | Durvalumab + Bevacizumab (anti-VEGFA) | RFS (Recurrence-Free Survival) |
| NCT03434379 | 3 | I | Atezolizumab (anti PD-L1) + Bevacizumab | PFS (Progression-Free Survival) OS |
| NCT02715531 | 1 | I | Atezolizumab + Bevacizumab | AEs (Adverse Events) OR (Objective Response) PFS |
| NCT03755791 | 3 | I | Cabozantinib (RTK inhibitor) + Atezolizumab | PFS OS |
| NCT03937830 | 2 | II | Durvalumab + Bevacizumab + Doxorubicin (TACE) | PFS |
| NCT02519348 | 2 | II | Durvalumab +/− Tremelimumab Tremelimumab +/− Durvalumab Durvalumab +/− Bevacizumab |
AEs DLT (Dose Limiting Toxicity) |